Watchman Laa denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for watchman laa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue an "Experimental or Investigational" Denial for the Watchman LAA Closure Device

The Watchman device has FDA approval and an established body of clinical evidence. However, Cigna may still issue an "experimental" denial when the specific use falls outside the approved indication — for example, in a patient population, anatomical variant, or clinical setting not covered by the FDA-cleared labeling. Cigna's coverage policies periodically lag behind evolving clinical evidence, which makes this type of denial one of the most commonly overturned on appeal.

## Why This Denial Is Appealable

FDA approval of the Watchman device establishes a strong foundation for appeal. If the procedure was performed for the approved indication in a qualifying patient, an "experimental" denial contradicts the device's regulatory status. Even where the use involves a nuanced clinical application, an IRO applying standard-of-care analysis frequently overturns these denials when the treating cardiologist provides robust clinical support.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Submit within the deadline on your denial notice. Include clinical literature and the FDA approval summary.
• External review: "Experimental" denials are among the most appropriate cases for IRO review under ACA §2719 external review. IROs are required to assess whether the treatment meets the standard of care using objective clinical evidence — not just the insurer's internal policy. The external review window is approximately four months from the final internal denial.
• Expedited review: Request if delay creates urgent clinical risk (e.g., continuing anticoagulation poses imminent serious bleeding risk).

## Documentation to Gather

1. FDA approval documentation: Include the FDA 510(k) clearance summary or approval letter for the Watchman device, demonstrating its approved status. 2. Indication-matching records: Chart documentation confirming the patient's diagnosis and that the procedure was performed for the FDA-approved indication. 3. Physician clinical-necessity letter: The treating cardiologist or electrophysiologist should address Cigna's "experimental" characterization directly, citing FDA approval and the recognized professional society guidelines (ACC/AHA/HRS) that endorse LAA closure. 4. Anticoagulation history: Documentation of why anticoagulation was not a durable option, reinforcing that this is standard-of-care management.

## Criteria-Mapping Structure

Request the exact Cigna coverage policy number and version used to deny the claim. Obtain the current version of that policy. Address every criterion listed as unmet. Provide the FDA approval documentation, the treating physician's letter, and the relevant guideline organization's endorsement. Present each point as a direct response to each denial criterion.